Abbreviations
5HT2c, 5-hydroxytryptamine receptor-2C; ACE, angiotensin-converting enzyme; ARB,
angiotensin receptor blockers; BMI, body mass index; BP, blood pressure; CVD, cardiovascular
disease; DMARD, disease-modifying antirheumatic drugs; EMA, European Medicines Agency;
ER, extended release; ES, Endocrine Society; GABA, gamma-amino-butyric acid; GLP-1,
glucagon-like peptide-1; HR, heart rate; HTN, hypertension; IUD, intrauterine device; MAO,
monoamine oxidase; NAFLD, nonalcoholic fatty liver disease; SGLT, sodium-glucose linked
transporter; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin
reuptake inhibitor; T2DM, type 2 diabetes mellitus
Source
Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological Management of Obesity:
An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab.
2015;100(2):342–62.
Grading System
Strength of
Recommendation
1 = strong 2 = less strong U = ungraded
Quality of
Evidence
⊕⊕⊕⊕
= high
⊕⊕⊕
= moderate
⊕⊕
= low
⊕
= very low
106 Commerce Street, Suite 105
Lake Mary, FL 32746
TEL: 407.878.7606 • FAX: 407.878.7611
Order additional copies, GuidelineCentral.com
Copyright © 2015 All rights reserved
ESOBE15093
Disclaimer
is Guideline attempts to define principles of practice that should produce high-quality patient care.
It focuses on the needs of primary care practice, but also is applicable to providers at all levels. is
Guideline should not be considered exclusive of other methods of care reasonably directed at obtaining
the same results. e ultimate judgment concerning the propriety of any course of conduct must be
made by the clinician aer consideration of each individual patient situation.
Neither IGC, the medical associations, nor the authors endorse any product or service associated with
the distributor of this clinical reference tool.